HUBRIPHAR SA replaced by HEMIGEST Ltd

Hubriphar has been incorporated as a Belgian limited liability company founded in 1992. Hubriphar owns 4 shares of H-Phar. Hubriphar has contributed in kind with HIV/AIDS and Immunology licences, its family of molecules and all its derivatives for all applications. The valuation related to the contribution in kind has been established based on real costs and was confirmed by an Auditor as requested by the Belgian Law. Hubriphar and H-Phar entered into a consulting agreement whereby Hubriphar offers, through Mrs. Margery and Dr. Vandevelde, to the Company, management services on a daily basis.

Mrs Hélène Margery co inventor owns 4020 shares of H-Phar , she is Chief Executive Officer

Mr Michel Vandevelde MD co inventor owns 2763 shares of H-Phar, he is Chairman of the Board

Avenue des bouvreuils .14, B-1301 Bierges, Belgium.
Tel: + 32.10.41.70.78 - Email hmatgery@arcadis.be

Mr Samyel CITGES

Mr Samyel Citges acts as a business Angel He owns 100 shares of H-Phar

Chaussée de Ninove,227 - 1700 Dilbeek Belgium

A new Swiss Investor will recapitalize in mid october 2010